Retina

Julie Rodman, OD, MS, FAAO, sits down with Optometry Times to discuss her anticipation for the future of technology in optometry, especially retinal care.

Ahead of her SECO presentations, Julie Rodman, OD, MS, FAAO, shares some tidbits of what attendees can expect.

The study examined changes in genes and proteins of the retinas of 9 strains of mice.

The study found that 17.4% of Medicare patients needed subspecialized procedures relative to 5.6% of surgeons practicing in rural areas between 2012 and 2022.

The agent class’s pleiotropic effects should keep optometrists vigilant.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

DRSS results remained stable or improved with OKT-TKI, and the drug was well-tolerated in the study.

The 3-year, $4.8 million award comes from the NIH Venture Program Oculomics Initiatives.

Preclinical studies evaluating NPI-001 have found that it boosts the endogenous antioxidant glutathione, which stops chemically aggressive oxygen molecules from further damaging retinal cells, according to Nacuity Pharmaceuticals.

Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

Nocturnal hypoxia could be a new additional modifiable risk factor for nAMD.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

A recent study evaluated both deep neural networks and aggregation functions to determine ways to improve schizophrenia detection.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).